AZATHIOPRINE-50 TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
11-02-2020
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
AZATHIOPRINE
から入手可能:
PRO DOC LIMITEE
ATCコード:
L04AX01
INN（国際名）:
AZATHIOPRINE
投薬量:
50MG
医薬品形態:
TABLET
構図:
AZATHIOPRINE 50MG
投与経路:
ORAL
パッケージ内のユニット:
100
処方タイプ:
Prescription
治療領域:
IMMUNOSUPPRESSIVE AGENTS
製品概要:
Active ingredient group (AIG) number: 0101830001; AHFS:
認証ステータス:
CANCELLED POST MARKET
承認日:
2023-07-10
製品の特徴
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AZATHIOPRINE-50
AZATHIOPRINE TABLETS USP
50 MG
IMMUNOSUPPRESSIVE AGENT
PRO DOC LTÉE
Date of Revision:
2925, Boul. Industriel,
February 11, 2020
Laval, Quebec
H7L 3W9
Submission Control No.: 235658
_AZATHIOPRINE-50 Product Monograph _
_ _
Page 2 of 29
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................................
3
SUMMARY PRODUCT INFORMATION
..................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................
3
WARNINGS AND PRECAUTIONS
............................................................................................................
4
ADVERSE REACTIONS
..............................................................................................................................
9
DRUG INTERACTIONS
............................................................................................................................
11
DOSAGE AND ADMINISTRATION
........................................................................................................
12
OVERDOSAGE
..........................................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
......................................................................................
13
STORAGE AND STABILITY
....................................................................................................................
15
SPECIAL HANDLING INSTRUCTIONS
.................................................................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................
完全なドキュメントを読む
